Who are Omalizumab Injection's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ANTI-IGE THERAPY (XOLAIR), Xolair injections, Omalizumab (Xolair), Omalizumab (CinnaGen), EU-approved Xolair.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/omalizumab-injection.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Omalizumab Injection — Competitive Intelligence Brief

Omalizumab Injection (Omalizumab Injection) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: IgE monoclonal antibody. Area: Immunology / Allergy / Respiratory.

marketed IgE monoclonal antibody Immunoglobulin E (IgE) Immunology / Allergy / Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Omalizumab Injection (Omalizumab Injection) — Rigshospitalet, Denmark. Omalizumab is a monoclonal antibody that binds to circulating immunoglobulin E (IgE), preventing IgE from interacting with high-affinity IgE receptors on mast cells and basophils.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Omalizumab Injection TARGET	Omalizumab Injection	Rigshospitalet, Denmark	marketed	IgE monoclonal antibody	Immunoglobulin E (IgE)
ANTI-IGE THERAPY (XOLAIR)	ANTI-IGE THERAPY (XOLAIR)	Children's Hospital of The King's Daughters	marketed	Anti-IgE monoclonal antibody	Immunoglobulin E (IgE)
Xolair injections	Xolair injections	University of California, Los Angeles	marketed	Anti-IgE monoclonal antibody	Immunoglobulin E (IgE)
Omalizumab (Xolair)	Omalizumab (Xolair)	McMaster University	marketed	IgE monoclonal antibody	Immunoglobulin E (IgE)
Omalizumab (CinnaGen)	Omalizumab (CinnaGen)	Cinnagen	phase 3	IgE monoclonal antibody	Immunoglobulin E (IgE)
EU-approved Xolair	EU-approved Xolair	Celltrion	phase 3	IgE monoclonal antibody	Immunoglobulin E (IgE)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (IgE monoclonal antibody class)

Celltrion · 1 drug in this class
Cinnagen · 1 drug in this class
McMaster University · 1 drug in this class
Rigshospitalet, Denmark · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Omalizumab Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/omalizumab-injection. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab